Facebook Linkedin RSS Twitter Youtube
Home 2023

Sarepta Therapeutics

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Artificial Intelligence

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment

Alex Philippidis -
22
Door Busters: Entrada Therapeutics Is Engaging Inaccessible Intracellular Targets
Drug Discovery

Door Busters: Entrada Therapeutics Is Engaging Inaccessible Intracellular Targets

Jonathan D Grinstein, PhD -
20
FDA Lifts Clinical Hold on Pfizer DMD Gene Therapy Linked to Patient Death
Drug Discovery

FDA Lifts Clinical Hold on Pfizer DMD Gene Therapy Linked to Patient Death

Alex Philippidis -
2
Top 5 Reasons behind the Biopharma Bear Market
GEN Edge

Top 5 Reasons behind the Biopharma Bear Market

Alex Philippidis -
0
Ten Life Science Analysts to Watch in 2020
A-Lists

Ten Life Science Analysts to Watch in 2020

Alex Philippidis -
0
Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+
Genome Editing

Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+

Alex Philippidis -
0
10 Takeover Targets to Watch This Fall
A-Lists

10 Takeover Targets to Watch This Fall

Alex Philippidis -
1
Sarepta to Acquire Myonexus for $165M, Broadening Muscular Dystrophy Gene Therapy Pipeline
Genome Editing

Sarepta to Acquire Myonexus for $165M, Broadening Muscular Dystrophy Gene Therapy Pipeline

Alex Philippidis -
0
Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302
News

Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302

GEN Staff Writer -
0
FDA Lifts Holds on Epizyme Cancer Candidate, Sarepta DMD Gene Therapy
News

FDA Lifts Holds on Epizyme Cancer Candidate, Sarepta DMD Gene Therapy

GEN Staff Writer -
0
12Page 1 of 2
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.